Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
216 hedge funds and large institutions have $2.46B invested in Revance Therapeutics, Inc. in 2023 Q1 according to their latest regulatory filings, with 50 funds opening new positions, 63 increasing their positions, 74 reducing their positions, and 25 closing their positions.
152% more call options, than puts
Call options by funds: $57.2M | Put options by funds: $22.6M
100% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 25
81% more capital invested
Capital invested by funds: $1.36B → $2.46B (+$1.1B)
12% more funds holding
Funds holding: 193 → 216 (+23)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
15% less repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 74
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$60.7M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
+$59M |
| 3 |
D.E. Shaw & Co
New York
|
+$29.7M |
| 4 |
Capital World Investors
Los Angeles,
California
|
+$18.6M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$17.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$29.1M |
| 2 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$21.2M |
| 3 |
PA
Perceptive Advisors
New York
|
-$13.5M |
| 4 |
Jennison Associates
New York
|
-$12.2M |
| 5 |
Millennium Management
New York
|
-$12M |
RVNC Hedge Fund Activity: Q1 2023 in Review
216 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q1 2023, worth a combined $2.46B — up 81% from $1.36B a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new RVNC positions and 25 closed out — a net gain of 25 holders — while 63 added to existing stakes and 74 trimmed.
The largest buyer was Thrivent Financial for Lutherans, adding an estimated $60.7M. The largest seller was BlackRock, cutting an estimated $29.1M.
- 216 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q1 2023, up from 193 in Q4 2022.
- Funds reported $2.46B of Revance Therapeutics, Inc. stock for Q1 2023, up 81% quarter-over-quarter.
- 50 funds opened new Revance Therapeutics, Inc. positions in Q1 2023 and 25 closed out, a net change of +25 holders.
- The largest Revance Therapeutics, Inc. buyer in Q1 2023 was Thrivent Financial for Lutherans, an estimated $60.7M added.
- The largest Revance Therapeutics, Inc. seller in Q1 2023 was BlackRock, an estimated $29.1M sold.
Based on aggregated 13F filings for Q1 2023.